⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2024Open Access

Supplementary Information from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

Mustafa Emre Gedik Özge Saatci Nathaniel Oberholtzer Meral Üner Özge Akbulut Metin Çetįn Mertkaya Aras Kübra İbiş Burcu Çalışkan Erden Banoğlu Stefan Wiemann Ayşegül Üner Sercan Aksoy Shikhar Mehrotra Özgür Şahin

View Full Paper

Ask AI

Bookmark

Share

Abstract

This file contains supplementary methods, 11 supplementary figures and 2 supplementary tables

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gedik et al. (2024) studied this question.

synapsesocial.com/papers/68e6be8ab6db64358763e1ef https://doi.org/10.1158/0008-5472.25735665

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Information from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer2024
2Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
3Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
4Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration2024
5Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration2024

More related papers

Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia2024
Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia2024
Supplementary Data from Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors2024